NCT05465707View on ClinicalTrials.gov

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 30, 2022

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

CM313 2 mg/kg

Once 1 week, intravenous infusion.

BIOLOGICAL

CM313 4 mg/kg

Once 1 week, intravenous infusion.

BIOLOGICAL

CM313 8 mg/kg

Once 1 week, intravenous infusion.

BIOLOGICAL

CM313 16 mg/kg

Once 1 week, intravenous infusion.

BIOLOGICAL

Placebo

Once 1 week, intravenous infusion.

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05465707 - A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter